MDBriefCase will be unavailable due to maintenance from Sunday, January 14 11PM to Monday, January 15 1AM ET.
Welcome
Did you know that COVID patients have nearly 16 times the risk of developing myocarditis compared to those not infected with COVID?
Patients with cardiac disease who develop COVID-19 are at higher risk of experiencing severe infection, complications, and death. In one systematic literature review, COVID-19 patients were more than three times as likely to die, experience severe disease, or be transferred to the intensive care unit and/or be placed on a ventilator. And in a report from the Chinese Centre for Disease Control and Prevention, the case fatality rate in patients with COVID-19 and cardiac disease (10.5 percent) was more than four times the overall mortality rate (2.3 percent).
Myocarditis and pericarditis are complications of COVID-19 infection. While most cases of myocarditis resolve on their own, it sometimes recurs and can lead to dilated cardiomyopathy. Pericarditis, though not generally serious itself, can cause serious health issues. These and other cardiovascular complications of COVID-19 are greatly increasing the burden of morbidity and mortality in adult patients.
Myocarditis and pericarditis have also been reported in adolescents and young adults following administration of mRNA SARS CoV-2 vaccines, primarily in male adolescents after the second dose of mRNA vaccine. This occurs rarely: according to a CDC estimate, the incidence of myocarditis due to mRNA vaccination is 1.2 per 100,000 doses in the 18-29 population.
Patients usually experience symptoms (chest pain, shortness of breath, sensation of fluttering or pounding heart) during the first week after being vaccinated. Most patients recover quickly with treatment and can resume regular activities of daily living once they have recuperated. Short-term follow up at between three and six months suggests that patients generally make a full recovery with no further symptoms and normal ventricular function (though those who have suffered myocarditis should check with a cardiologist before restarting athletic activities). Death following myocarditis is rare; an international review of mortality after COVID-19 vaccination found only two confirmed cases of myocarditis-induced fatality. In spite of the mRNA vaccine-related risk of myocarditis and pericarditis, it seems that the risk is well worth the benefit of preventing infection with COVID-19.
While the benefits of vaccination probably outweigh the risk of myocarditis and pericarditis for the general population, we cannot be sure that the same is true for a particular population: patients with cardiac disease. Are they more vulnerable to COVID-19? Should they be vaccinated? And what role can healthcare providers play in monitoring and managing heart disease patients following vaccination and during and after COVID-19 infection?
The currently available evidence suggests that vaccination is an option for patients living with heart disease. First, myocarditis and pericarditis are rare consequences of COVID-19 vaccination. Secondly, they primarily occur in individuals less than thirty years of age, whereas cardiovascular disease is more likely to occur in those who are at least 65 years of age. Finally, the greater risk of severe illness and death due to COVID-19 among individuals with heart disease suggests that the small risk of myocarditis and pericarditis is preferable to the chances of developing cardiac complications because of contracting COVID-19.
Healthcare professionals can encourage patients to self-monitor for symptoms of myocarditis and pericarditis (chest pain, palpitations, shortness of breath) following immunization and to seek medical attention if they experience these symptoms. For any suspected case of myocarditis or pericarditis, consult with a cardiologist. Treatment can include supportive care, NSAIDs, colchicine, steroids, and intravenous immunoglobulin and steroids for patients up to 18 years of age.
As the majority of cases are mild and do not require medical measures or hospitalization, many patients can be assessed remotely. However, clinicians should be alert for any symptoms suggestive of cardiac disease in outpatients.
In hospitals, healthcare providers should conduct a targeted cardiac evaluation for patients with COVID-19 who develop one or more of the common cardiac complications of the disease (including heart failure or cardiac arrhythmia).Supportive cardiac care is recommended for these patients.
Join the MDBC Community for free to receive the latest clinical updates and guidelines.
Explore Clinical Paper Highlights on Bench to Practice: Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination Bench to Practice is a new educational hub for up-to-date clinical research and resources for healthcare professionals. The Clinical paper highlights section provides comprehensive summaries of recent clinical papers in 10 minutes. Explore more paper highlights here.
199 Bay Street #4000, Toronto,
ON M5L 1A9
In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Lab website (the “Website”), you (“You”) expressly agree to the following:
Review: MDBriefCase is pleased to consider the publication of Your Work on the Website. The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.
Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered. If posted, You will be identified as the author of the Work, or co-author if applicable.
Grant of Rights: As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats: (1) the exclusive right of first publication worldwide; (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications. The grant of rights survives termination or expiration of this Agreement.
Warranty: You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work. This warranty survives termination or expiration of this Agreement.
Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Lab website.
The Healthcare Leadership Lab welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished. When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.
Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.
Guest articles for the MDBriefCase Healthcare Leadership Lab may run between 500 and 1000 words.
MDBriefCase reserves the right to accept or reject any submission and the right to condition acceptance upon revision of material to conform to its criteria.
There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal websites, corporate websites and social media platforms.
Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement.
